MarketPeel
Insider Trading Intelligence
Pricing
…
AM

Anand Mehra

ACRS
DIRECTOR · ACLARIS THERAPEUTICS, INC. · CIK 0001590102
FILING MIX · LIFETIME73%/27%
BUYS
24
SELLS
9
TOTAL VALUE
$1.77M
COMPANIES
1
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
0
AVG SELL PX
—
TRADE KIND
SHOWING 33 / 33
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Anand Mehra, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-20.91%+1.75%-22.67%-22.67%—
14d1+0.00%-16.23%+2.31%-18.54%-18.54%—
30d1+0.00%-39.65%-0.71%-38.94%-38.94%—
60d1+0.00%-44.01%+1.57%-45.58%-45.58%—
90d1+0.00%-49.89%+3.94%-53.83%-53.83%—
180d1+0.00%-71.68%+1.41%-73.09%-73.09%—
1y1+0.00%-46.41%+12.97%-59.38%-59.38%—
2y1(1 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ACRS · 0 shares · as of Jun 5, 2026
0181,601363,202544,802726,403202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 24 buys / 9 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ACRS
ACLARIS THERAPEUTICS, INC.
SALE
11,580——0Jun 5, 2026Jun 8, 2026 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASE
11,580——726,403Jun 5, 2026Jun 8, 2026 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
42,350——42,350Jun 4, 2026Jun 8, 2026 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,987——10,987Jun 4, 2026Jun 8, 2026 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASE
4,793——714,823Jun 6, 2025Jun 9, 2025 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
SALE
4,793——0Jun 6, 2025Jun 9, 2025 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,580——11,580Jun 5, 2025Jun 9, 2025 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
42,350——42,350Jun 5, 2025Jun 9, 2025 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASE
666,666$2.25$1.50M710,030Nov 19, 2024Nov 20, 2024 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,750——15,750Jun 6, 2024Jun 10, 2024 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,793——4,793Jun 6, 2024Jun 10, 2024 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
SALE
4,660——0Jun 1, 2024Jun 4, 2024 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASE
4,660——43,364Jun 1, 2024Jun 4, 2024 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
SALE
4,507——0Jun 2, 2023Jun 5, 2023 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASE
4,507——38,704Jun 2, 2023Jun 5, 2023 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,750——15,750Jun 1, 2023Jun 5, 2023 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,660——4,660Jun 1, 2023Jun 5, 2023 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
SALE
3,356——0Jun 3, 2022Jun 6, 2022 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASE
3,356——34,197Jun 3, 2022Jun 6, 2022 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,507——4,507Jun 2, 2022Jun 6, 2022 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,750——15,750Jun 2, 2022Jun 6, 2022 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,356——3,356Jun 3, 2021Jun 4, 2021 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
12,250——12,250Jun 3, 2021Jun 4, 2021 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASE
8,000$18.35$146.8K24,209Feb 2, 2021Feb 3, 2021 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
SALE
8,000——0Feb 2, 2021Feb 3, 2021 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASE
6,632$18.32$121.5K30,841Feb 2, 2021Feb 3, 2021 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
SALE
6,632——0Feb 2, 2021Feb 3, 2021 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
SALE
7,333——0Jun 6, 2020Jun 8, 2020 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASE
7,333——16,209Jun 6, 2020Jun 8, 2020 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,500——16,500Jun 4, 2020Jun 8, 2020 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASE
8,876——8,876Mar 2, 2020Mar 4, 2020 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
SALE
8,876——0Mar 2, 2020Mar 4, 2020 ↗View →
ACRS
ACLARIS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,876——8,876Mar 2, 2020Mar 4, 2020 ↗View →
Other insiders · ACRS
Loading peer insiders…
About this filer
CIK 0001590102
ROLE
Director
PRIMARY
ACRS
COMPANIES
1
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001590102DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback